Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I Me1-14 F(ab')2 in Leptomeningeal Metastases
NCT00002751Phase 2Completed
- Sponsor
- Duke University
- Start
- Jul 1989
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 131I-Me1-14 F(ab')2 in leptomeningeal metastasis (LM), sponsored by Duke University. Primary endpoints: Maximum Tolerated Dose, Toxicity and 1 more. Started Jul 1989; status: completed.
02
Drugs
131I-Me1-14 F(ab')2
03
Conditions
leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT00002751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002751.